<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7029664/results/search/test_trace/results.xml">
  <result pre="cases of HCV-infected children are rarely reported in Korea. The" exact="prevalence" post="of HCV immunoglobulin G (IgG) positivity among Korean adolescents"/>
  <result pre="not spread by casual contact. The main route of HCV" exact="infection" post="in children is vertical transmission by infected mothers [1]."/>
  <result pre="no protective vaccine against HCV. The framework for treating HCV" exact="infection" post="is changing rapidly. New short-course oral direct-acting antiviral (DAA)"/>
  <result pre="the European Medicines Agency have approved DAA regimens for the" exact="treatment" post="of adults with chronic HCV infection. Both agencies approved"/>
  <result pre="3 to less than 12 years. In June 2019, 12-week" exact="treatment" post="with ledipasvir/sofosbuvir for any genotype was approved for Korean"/>
  <result pre="DAA regimen, the sustained virologic response at 12 weeks after" exact="treatment" post="was 98%–100% in cases of approved DAA or currently"/>
  <result pre="ribavirin, measured by sustained virologic response at 24 weeks after" exact="treatment" post="was 93% in patients with genotype 2 or 3,"/>
  <result pre="et al. [5] investigated thyroid dysfunction in children with HCV" exact="infection" post="receiving PegIFN plus ribavirin and showed that 28% of"/>
  <result pre="Although PegIFN plus ribavirin is approved for children with HCV" exact="infection" post="(age ≥3 years), IFN treatment is no longer recommended"/>
  <result pre="approved for children with HCV infection (age ≥3 years), IFN" exact="treatment" post="is no longer recommended for children in the DAA"/>
  <result pre="such as the occurrence of advanced fibrosis [1,8]. Deferring IFN" exact="treatment" post="is recommended until DAA regimens are approved for children"/>
  <result pre="the first year of life for perinatally exposed children, and" exact="screening" post="should be repeated after 3 years of age in"/>
  <result pre="References References 1collab: World Health OrganizationGuidelines for the care and" exact="treatment" post="of persons diagnosed with chronic hepatitis C virus infection"/>
  <result pre="and treatment of persons diagnosed with chronic hepatitis C virus" exact="infection" post="[Internet]Geneva (Switzerland)World Health Organization2018[cited 2019 Sep 15]. Available from:"/>
  <result pre="risk factors for thyroid dysfunction during peginterferon α and ribavirin" exact="treatment" post="in patients with chronic hepatitis CKorean J Intern Med20153079280026552454"/>
 </snippets>
</snippetsTree>
